Literature DB >> 19543768

Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT).

Paolo Vescovi1, Maddalena Manfredi, Elisabetta Merigo, Marco Meleti, Carlo Fornaini, Jean-Paul Rocca, Samir Nammour.   

Abstract

Osteonecrosis of the jaw (ONJ) in patients on long-term bisphosphonate Therapy (BPT) has been reported with increasing frequency in literature over the past 4 years. Therapy for this condition is still a dilemma. Temporary suspension of BPT offers no short-term benefits; hyperbaric oxygen has no proven efficacy and therefore is not recommended. Intermittent or continuous antibiotic therapy with surgical debridement can be beneficial to palliate the symptoms. Er:YAG laser can be used to eliminate necrotic bone portions by partial or total resection as an alternative to conventional rotary devices. In our study, 91 patients affected by ONJ-BP lesion, for a total of 115 ONJ sites were observed between January 2004 and May 2008 (Department of Odontostomatology, University of Parma). Fifty-five ONJ sites were considered for this study in four different groups, retrospectively identified on the basis of treatment performed (G1-G4). G1: 13 ONJ-BP sites were treated with medical therapy (amoxicillin 1gr x 3/die per os with metronidazole 250 mg x 2/die per os) for at least 2 weeks; G2: 17 ONJ-BP sites received medical treatment in association with cycles of low-level laser therapy (LLLT) applications performed using an Nd:YAG laser (1,064 nm) once a week for 2 months; G3: 13 ONJ-BP sites were surgically treated (sequestrectomy of necrotic bone, debridement, corticotomy/surgical removal of alveolar and/or cortical bone); G4: 12 ONJ-BP sites were treated with surgical therapy performed using an Er:YAG laser (2,940 nm) in association with LLLT. Clinical success has been defined for each treatment performed as: (a) complete mucosal healing free from signs and symptoms (classified as stage "0") or (b) transition from a higher to a lower stage (Ruggiero staging) for at least 3 months. All the ONJ-BP sites treated with Er:YAG laser (G4 group) had a clinical improvement (100%) and 87.5% of sites had a complete mucosal healing with a mean follow-up of 13 months. The result obtained in the G4 is extremely significant in comparison with those obtained by medical treatment alone or in a traditional surgical approach. Thanks to the high degree of affinity of this wavelength for water and hydroxyapatite, both soft and bone tissues can be easily treated. This technique can also be used for conservative operations whereby necrotic bone is vaporized until healthy bone is reached. In addition, an additional advantage of the Er:YAG laser is its bactericidal and possible biostimulatory action, accelerating the healing of both soft tissues and bone tissues, in comparison to conventional treatments. In conclusion, from our experience, it is possible to observe that an early conservative surgical approach with Er:YAG laser associated with LLLT, for BP-induced ONJ could be considered as more efficient in comparison with medical therapy or other conventional techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543768     DOI: 10.1007/s10103-009-0687-y

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  30 in total

1.  Er:YAG laser therapy for peri-implant infection: a histological study.

Authors:  Aristeo Atsushi Takasaki; Akira Aoki; Koji Mizutani; Shigenari Kikuchi; Shigeru Oda; Isao Ishikawa
Journal:  Lasers Med Sci       Date:  2007-01-12       Impact factor: 3.161

2.  Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws.

Authors:  Paolo Vescovi; Maddalena Manfredi; Elisabetta Merigo; Marco Meleti
Journal:  J Oral Maxillofac Surg       Date:  2008-04       Impact factor: 1.895

3.  Low-level laser irradiation promotes cell proliferation and mRNA expression of type I collagen and decorin in porcine Achilles tendon fibroblasts in vitro.

Authors:  Chia-Hsin Chen; Jin-Lian Tsai; Yan-Hsiung Wang; Chia-Ling Lee; June-Kai Chen; Mao-Hsiung Huang
Journal:  J Orthop Res       Date:  2009-05       Impact factor: 3.494

4.  Antimicrobial effects of 2.94 microm Er:YAG laser radiation on root surfaces: an in vitro study.

Authors:  Matthias Folwaczny; Albert Mehl; Hans Aggstaller; Reinhard Hickel
Journal:  J Clin Periodontol       Date:  2002-01       Impact factor: 8.728

5.  Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.

Authors:  Gianluigi Ferretti; Alessandra Fabi; Paolo Carlini; Paola Papaldo; Paola Cordiali Fei; Serena Di Cosimo; Nello Salesi; Diana Giannarelli; Andrea Alimonti; Barbara Di Cocco; Giovanna D'Agosto; Valentina Bordignon; Elisabetta Trento; Francesco Cognetti
Journal:  Oncology       Date:  2005-08-02       Impact factor: 2.935

Review 6.  [The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects].

Authors:  A Corrado; F P Cantatore
Journal:  Reumatismo       Date:  2005 Jul-Sep

7.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

8.  Surgical therapy for osteonecotic lesions of the jaws in patients in therapy with bisphosphonates.

Authors:  Gianluigi Longobardi; Roberto Boniello; Giulio Gasparini; Immacolata Pagano; Sandro Pelo
Journal:  J Craniofac Surg       Date:  2007-09       Impact factor: 1.046

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.

Authors:  Paolo Vescovi; Elisabetta Merigo; Maddalena Manfredi; Marco Meleti; Carlo Fornaini; Mauro Bonanini; Jean Paul Rocca; Samir Nammour
Journal:  Photomed Laser Surg       Date:  2008-02       Impact factor: 2.796

View more
  32 in total

Review 1.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 2.  Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Victoria Rollason; Alexandra Laverrière; Laura C I MacDonald; Tanya Walsh; Martin R Tramèr; Nicole B Vogt-Ferrier
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

3.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

4.  Treatment of bisphosphonate-induced osteonecrosis of the jaws with Nd:YAG laser biostimulation.

Authors:  Marita Luomanen; Satu Alaluusua
Journal:  Lasers Med Sci       Date:  2011-05-20       Impact factor: 3.161

Review 5.  Application of laser in oral surgery.

Authors:  Mohammad Asnaashari; Saeede Zadsirjan
Journal:  J Lasers Med Sci       Date:  2014

6.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

7.  Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.

Authors:  Sandra R Torres; Curtis S K Chen; Brian G Leroux; Peggy P Lee; Lars G Hollender; Michelle Lloid; Shane Patrick Drew; Mark M Schubert
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-02-14

8.  The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.

Authors:  A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter
Journal:  Clin Oral Investig       Date:  2016-05-12       Impact factor: 3.573

9.  Bisphosphonates and osteonecrosis: an open matter.

Authors:  Paolo Vescovi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

10.  Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors:  Christian Thomas; Magdalena Spanidis; Christina Engel; Frederik C Roos; Sebastian Frees; Andreas Neisius; Christian Hampel; Peter Rubenwolf; Joachim W Thüroff; Christian Walter; Matthias Miederer
Journal:  Clin Oral Investig       Date:  2015-08-26       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.